Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 5/20 | 0.43 |
| ▸ | PPARG | P37231 | 4/20 | 0.43 |
| ▸ | CTSS | P25774 | 4/20 | 0.43 |
| ▸ | CTSK | P43235 | 3/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 2/20 | 0.42 |
| ▸ | CTSL | P07711 | 2/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4816579 | 1.00 | EPHX2 (0.44) | EPHX2PPARAPPARGCTSSCTSK | |
| SCHEMBL5389519 | 1.00 | EPHX2 (0.44) | EPHX2PPARAPPARGCTSSCTSK | |
| SCHEMBL1598690 | 1.00 | EPHX2 (0.44) | EPHX2PPARAPPARGCTSSCTSK | |
| SCHEMBL23201199 | 0.87 | AAK1 (0.43) | EPHX2PPARAPPARGCTSSCTSK | |
| SCHEMBL30882362 | 0.87 | AAK1 (0.43) | EPHX2PPARAPPARGCTSSCTSK | |
| SCHEMBL23201197 | 0.87 | AAK1 (0.43) | EPHX2PPARAPPARGCTSSCTSK | |
| SCHEMBL27923521 | 0.87 | GRM7 (0.40) | EPHX2 | |
| SCHEMBL239019 | 0.87 | GRM7 (0.40) | EPHX2 | |
| SCHEMBL23201200 | 0.84 | ACE (0.41) | EPHX2PPARAPPARGCTSSCTSK | |
| SCHEMBL8578804 | 0.84 | AAK1 (0.42) | EPHX2PPARAPPARGCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107097-A1 | SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF | ENLAZA THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| EP-4532564-A1 | CROSSLINKING MULTISPECIFIC ANTIBODIES | Enlaza Therapeutics, Inc. (US) | 2025-04-09 | — | — | EP | disclosed |
| CN-119752820-A | Bioreactive compositions and methods of use thereof | 加利福尼亚大学董事会 | 2025-04-04 | — | — | CN | disclosed |
| CN-119731211-A | Cross-linked multispecific antibodies | 恩拉扎治疗公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-119136842-A | Cyclodextrin complexes that specialize in resolution mediators | 西蒂斯制药有限责任公司 | 2024-12-13 | — | — | CN | disclosed |
| EP-4452333-A1 | CROSSLINKING ANTIBODIES | Enlaza Therapeutics, Inc. (US) | 2024-10-30 | — | — | EP | disclosed |
| CN-111902394-B | Compositions and methods relating to salts of specific pro-inflammatory regressive mediators | 西蒂斯制药有限责任公司 | 2024-03-08 | — | — | CN | disclosed |
| EP-4301767-A1 | BIOREACTIVE COMPOUNDS AND METHODS OF USE THEREOF | The Regents of the University of California (US) | 2024-01-10 | — | — | EP | disclosed |
| WO-2023230582-A1 | CROSSLINKING MULTISPECIFIC ANTIBODIES | ENLAZA THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | WO | disclosed |
| CN-117098768-A | Biologically reactive compounds and methods of use thereof | 加利福尼亚大学董事会 | 2023-11-21 | — | — | CN | disclosed |
| WO-2023122753-A1 | CROSSLINKING ANTIBODIES | ENLAZA THERAPEUTICS, INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| CN-115666538-A | FEM1B protein binding agents and uses thereof | 加利福尼亚大学董事会 | 2023-01-31 | — | — | CN | disclosed |
| CN-109562186-B | Compositions and methods relating to salts of specialized proresolving mediators | 西蒂斯制药有限责任公司 | 2022-09-13 | — | — | CN | disclosed |
| WO-2022187273-A1 | BIOREACTIVE COMPOUNDS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-09-09 | — | — | WO | disclosed |